Thursday, August 13 @ 12:00 pm
The National Forum for Heart Disease & Stroke Prevention and 23 other organizations representing patients, healthcare providers, public health, payers and purchasers called on Congress and the Trump Administration to implement policies that will expand access to care options for patients nationwide, especially in underserved or otherwise vulnerable populations. This builds on a Joint Policy Statement issued by members and partners of the National Forum’s Value & Access Initiative, with recommendations that would enable people to obtain more healthcare services from pharmacists, often closer to where people live or work.
Enhance health and well-being by supporting people’s access to evidence-based care that is appropriate for them by:
The Steering Committee will share research, facts, best practices and policies to advance the consensus goal through its Action Agenda.
Highlight a way for all stakeholders to communicate, share evidence, best practices & identify areas for improvement
Identify effective and scalable shared-decision making tools and models
Identify and endorse or highlight models, research, tools and resources
Identify & support effective leverage points already underway that meet stakeholder needs
Through the Value & Access initiative, the following resources have been developed.
National Forum landscape report reveals how patients, providers, payers, public health and industry view the value of therapies and what access means to them.
SHARED Decision Making Tool for Patients & Providers – Worksheets designed for patients and providers to use in role modeling conversation on discussing FH (familial hypercholesterolemia) and Statin-Related Side Effects, and Atheriosclerotic Cardiovascular Disease (ASCVD) treatment options, concerns, preferences, and goals created in collaboration with the FH Foundation, National Lipid Association, and American Pharmacists Association Foundation.
A checklist modeling processes for P&T Committees to consider when managing the formulary system in making equitable coverage decisions, focusing on evidence-based processes to select and promote treatments offering the best therapeutic outcomes, while minimizing potential risks and costs to patients.
The steering committee includes a broad range of experts representing public health, patients, providers, payers, and pharma/biotech.